Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04599010 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of Body Composition in Large for Gestational Age Infants (LGA) With Oral Feeding Difficulty

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date: Aug 31, 2026 to Jul 31, 2027
    • Study completion date: Feb 28, 2027 to Dec 31, 2027
    v19
  2. Notable Start date: Aug 27, 2024 to Sep 26, 2024
    • Primary completion date: May 1, 2026 to Aug 31, 2026
    • Study completion date: Jun 1, 2026 to Feb 28, 2027
    v18
  3. Minor Site details revised at 1 of 2 sitesv17
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2024 to Aug 27, 2024
    • Site details revised at 2 of 2 sites
    v16
  5. Minor Start date: Aug 10, 2024 to Sep 1, 2024v15
Show 13 earlier versionsHide 13 earlier versions
  1. Minor Start date: Jul 15, 2024 to Aug 10, 2024v14
  2. Minor Primary completion date: May 2026 to May 1, 2026
    • Study completion date: Jun 2026 to Jun 1, 2026
    v13
  3. Notable Start date: May 15, 2024 to Jul 15, 2024
    • Study sites revised (2)
    • Collaborator revised
    v12
  4. Notable Start date: Mar 15, 2024 to May 15, 2024v11
  5. Notable Start date: Jan 15, 2024 to Mar 15, 2024v10
  6. Notable Start date: Oct 1, 2023 to Jan 15, 2024v9
  7. Notable Start date: Aug 1, 2023 to Oct 1, 2023
    • Primary completion date: May 31, 2026 to May 2026
    • Study completion date: Jul 31, 2026 to Jun 2026
    v8
  8. Notable Primary completion date: Jun 30, 2025 to May 31, 2026
    • Start date: Apr 1, 2023 to Aug 1, 2023
    • Study completion date: Mar 31, 2026 to Jul 31, 2026
    v7
  9. Notable Primary endpoint revised
    • Eligibility criteria revised
    • Study title revised
    v6
  10. Notable Phase: Phase 2/3 to Not applicablev5 Show 7 more changesShow less
    • Primary completion date: Jun 30, 2024 to Jun 30, 2025
    • Start date: Jul 1, 2022 to Apr 1, 2023
    • Primary endpoint revised
    • Study completion date: Dec 30, 2024 to Mar 31, 2026
    • Eligibility criteria revised
    • Secondary endpoints: 4 to 6
    • Study description revised
  11. Notable Phase: Not applicable to Phase 2/3v4
  12. Minor Re-verified, no change to tracked fieldsv3
  13. Notable Primary completion date: Jun 30, 2023 to Jun 30, 2024v2 Show 9 more changesShow less
    • Start date: Sep 1, 2021 to Jul 1, 2022
    • Primary endpoint revised
    • Enrollment target: 30 to 40
    • Study sites: 0 to 2
    • Study completion date: Aug 30, 2023 to Dec 30, 2024
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 85 words
    • Study title expanded, about 5 words
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Large for Gestational Age (LGA) infants have excess fat-mass (FM) proportion secondary to prolonged in utero exposure to an energy-rich environment. Our preliminary data suggest that excess FM proportion can be associated with oral feeding delay and a potentially modifiable therapeutic target to improve oral feeding outcomes. The objective of this study is to determine the impact of a short-term Fat-free mass (FFM)-indexed feeding on the oral intake volumes in LGA infants with oral feeding difficulties.
Trial Details
NCT Number NCT04599010
Lead Sponsor Nemours Children's Clinic
Collaborators: Emory University
Conditions
(from sponsor)
Body Composition, Feeding; Difficult, Newborn, Nutrition Disorder, Infant
Related terms Infant Nutrition Disorders
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov